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Abstract 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an 
expansion of CAG repeats in the huntingtin (Htt) gene. Despite intensive efforts devoted to 
investigating the mechanisms of its pathogenesis, effective treatments for this devastating disease 
remain unavailable. The lack of suitable models recapitulating the entire spectrum of the degenerative 
process has severely hindered the identification and validation of therapeutic strategies. The discovery 
that the degeneration in HD is caused by a mutation in a single gene has offered new opportunities to 
develop experimental models of HD, ranging from in vitro models to transgenic primates. However, 
recent advances in viral-vector technology provide promising alternatives based on the direct transfer 
of genes to selected sub-regions of the brain. Rodent studies have shown that overexpression of 
mutant human Htt in the striatum using adeno-associated virus or lentivirus vectors induces 
progressive neurodegeneration, which resembles that seen in HD. This article highlights progress 
made in modeling HD using viral vector gene transfer. We describe data obtained with of this highly 
flexible approach for the targeted overexpression of a disease-causing gene. The ability to deliver 
mutant Htt to specific tissues has opened pathological processes to experimental analysis and allowed 
targeted therapeutic development in rodent and primate pre-clinical models.  
 
Introduction  
Huntington’s disease (HD) is a progressive and devastating neurodegenerative disorder 
characterized by choreiform movements, cognitive deficits and psychiatric dysfunction (Vonsattel et 
al., 1985). This autosomal dominant hereditary brain disorder is caused by the presence of multiple 
CAG repeats in exon 1 of the huntingtin (Htt) gene, which encode an abnormally long stretch of 
glutamine residues. This mutation leads to neuronal degeneration and cell loss, most prominently in 
the striatum (The Huntington's Disease Collaborative Research Group, 1993). Post-mortem analysis 
shows ubiquitinated intranuclear inclusions, suggesting abnormal processing/folding of the 
polyglutamine (polyQ) domain in affected cells. However, the pathogenic mechanisms leading to 
neurodegeneration have yet to be discovered. HD affects approximately 1 in 10,000 people worldwide 
(Myers et al., 1993) with its symptoms generally beginning at age 40-50 and having a mean duration 
of 15-20 years. Since the identification of the gene mutation responsible for HD, important advances 
have been made in understanding the disease, but much is still unknown and fundamental questions 
remain.  
HD as a monogenic disorder can serve as model for the study of other more common 
neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders 
all share features including: delayed onset; selective neuronal vulnerability despite widespread 
expression of disease-related proteins during the entire lifetime of the individual; abnormal protein 
processing and aggregation; and cellular toxicity involving both autonomous and cell-cell interaction 
mechanisms. To develop effective treatments and understand HD pathogenesis, the development of 
animal models is critical. Since the cloning of the Htt gene and identification of the mutation as a CAG 
expansion in the region that encodes the N-terminal part of the protein, numerous in vivo genetic 
models have been developed. Although transgenic models reproduce the typical signs of early HD, 
current models do not fully recapitulate all the features of late stages of the pathology, including the 
severe striatal degeneration and the some motor and cognitive deficits observed in HD patients. 
Consequently, despite the information gained from such models, critical questions concerning HD 
pathogenesis and disease progression, and their relationship to the motor and cognitive symptoms 
typical of HD remain largely unanswered.  
The emergence of highly efficient viral vectors for CNS applications offers an approach to 
overcoming some of these limitations. Currently, gene transfer into the brain is a versatile and potent 
tool for neuroscientists, which is widely employed to decipher the mechanisms implicated in 
neurodegenerative diseases. It has been proposed that these very same vectors be used to 
overexpress disease-causing genes and develop new models of neurodegenerative diseases. 
Different vectors have been extensively studied but lentiviral and adeno-associated viral vectors have 
emerged as the most promising candidates. This review will discuss the progress made so far in gene 
transfer-based models of HD.  
 
Huntington’s disease, a model for CNS disorders  
HD can be considered as a prototypal model of a monogenic, fully penetrant 
neurodegenerative disorder characterized by an accumulation of misfolded protein. The Htt gene was 
discovered 18 years ago and has greatly accelerated our understanding of the pathogenesis. The 
disease is inherited in an autosomal dominant manner with age-dependent penetrance (Langbehn et 
al., 2004). Individuals at risk of inheriting the expanded CAG repeat can be identified before clinical 
onset of the disease by predictive genetic testing. Formal diagnosis of HD is made on the basis of 
characteristic extrapyramidal motor signs of chorea (Huntington Study Group, 1996). Generally, 
clinical symptoms develop very rapidly after onset and consist of motor symptoms characterized by 
hyperkinesia, which evolve to hypokinesia with bradykinesia, rigidity and dystonia. Typically, the 
earliest motor signs are eye movement abnormalities, followed by the progressive appearance of 
orofacial dyskinesia, involving the head, neck, trunk and arms before becoming chorea (Brouillet et al., 
1999). Cognitive dysfunction includes dementia characterized by difficulties in retrieving memories, 
slowed information processing and cognitive inflexibility (Cummings, 1995; Lawrence et al., 1996). 
Psychiatric disturbances most commonly manifest as apathy and depression (Wang and Qin, 2006). 
The most striking neuropathological feature of HD is marked atrophy of the caudate and putamen 
within the basal ganglia. In addition, the neuronal loss in the striatum is accompanied by pronounced 
gliosis (Vonsattel et al., 1985). Interestingly, many studies have consistently shown that the 
degenerative process does not equally affect all striatal cells, but preferentially affects GABAergic, 
medium-sized spiny neurons; (Cicchetti and Parent, 1996; Ferrante et al., 1987; Ferrante et al., 1985; 
Kowall et al., 1993). Although the striatum is the most profoundly affected region, neuronal loss may 
also occur in the cortex, thalamus, substantia nigra, hypothalamus and deep cerebellar nuclei. Since 
the genetic cause of HD was uncovered in 1993, several hypotheses have been put forward to explain 
the toxicity of mutant Htt, including excitotoxicity, oxidative stress, impaired energy metabolism, and 
abnormal protein-protein interactions, which in turn may cause transcriptional dysregulation (Crook 
and Housman, 2011). The cellular functions of wild-type Htt are still only partially understood 
(Cattaneo et al., 2005). Htt shuttles into the nucleus, has a role in vesicle transport, and can regulate 
gene transcription or RNA trafficking. Furthermore, Htt is necessary for early embryonic development. 
Most available evidence, including its dominant genetic transmission, the presence of abnormal 
protein aggregates, and the findings of biochemical, cell, and mouse model studies, suggests that HD 
arises predominantly from the gain of a toxic function produced by the abnormal conformation of 
mutant Htt (Shao et al., 2008; Tobin and Signer, 2000). Much of what we know about HD biology 
arises from the study of model systems.  
 
Modeling Huntington’s disease  
Cellular models. Cell lines are valuable for biochemical investigations and are particularly suitable for 
transient, stable or inducible expression strategies. On the other hand, primary neurons or mixed 
cultures reproduce some cell-cell interactions, though not all the complexities of neuronal circuits, and 
these cultures have been extensively used to study disease pathogenesis and therapeutic screening. 
One can notably mention a number of in vitro models based on cells of neuronal origin (Lunkes and 
Mandel, 1998), transfected neuronal cell lines (Cooper et al., 1998; Liu, 1998) , primary neurons 
derived from transgenic HD mouse models (Petersen et al., 2001; Saudou et al., 1998), and striatal 
cells isolated from knock-in mice (Trettel et al., 2000). However, in some of these in vitro models the 
expression of mutant Htt does not lead to cell death (Petersen et al., 2001), whereas others generate 
cell yields insufficient for extensive experimentation (Saudou et al., 1998). Recently, induced 
pluripotent stem cells were derived from HD patients to investigate mutant Htt-related phenotypes 
such as toxic effects or changes in cell metabolism (Park et al., 2008).  
Invertebrate models: Drosophila and Caenorhabditis elegans expressing mutant Htt proteins display 
progressive behavioral changes and neuronal degeneration. These features facilitate the study of 
molecular pathogenesis and provide a rapid initial screen of potential therapeutic interventions (Bates 
and Hockly, 2003). Jackson et al. created an HD model in Drosophila by expressing truncated wild-
type and mutant forms of Htt and demonstrated that extensive polyQ expansion led to repeat length-
dependent nuclear aggregation and severe and age-dependent degeneration (Jackson et al., 1998). 
However, the extent to which these models recapitulate HD biology is still uncertain.  
Mammalian models: The first animal models of HD were generated through the use of toxins (McGeer 
and McGeer, 1976). These early studies focused mainly on mitochondrial impairment and 
excitotoxicity-induced cell death, which have been described in HD brains (Beal et al., 1993; Brouillet 
et al., 1995). In 1996, a transgenic mouse model was generated by introducing a fragment of a 
juvenile HD patient’s Htt gene into the mouse genome (Mangiarini et al., 1996). This model revealed 
that the expression of exon 1 alone, containing a CAG expansion, was sufficient to produce some of 
the neuropathological features of HD. To further address specific pathways in the cascade of 
pathogenic events, new transgenic mice and rats have been created (Gray et al., 2008; Hodgson et 
al., 1999; Schilling et al., 1999). These HD models were produced by overexpressing either gene 
fragments of (N171-82Q mice, short stop, Exon 2) or the entire (BACHD and YAC models) human Htt 
gene carrying the expanded CAG repeats, and also by knocking the human Htt gene into the 
corresponding mouse gene locus (Levine et al., 1999; Lin et al., 2001; Menalled et al., 2002; 
Shelbourne et al., 1999; Wheeler et al., 1999). These models share behavioral deficits such as motor 
symptoms assessed by the rotarod test, electrophysiological alterations, striatal neuron atrophy, the 
presence of intranuclear inclusions, and altered transcriptional profiles. However, clear differences 
exist among the various transgenic models and some cardinal features of HD pathology are poorly 
reproduced, including severe neuronal degeneration and reduced life span (reviewed in Crook and 
Housman, 2011). Mouse models expressing N-terminal fragments of Htt have the most robust and 
rapidly progressive phenotypes and thus have been frequently used for therapeutic trials. Mice 
overexpressing full-length Htt generally present more subtle phenotypes but exhibit 
neurodegeneration that may be somewhat more selective than other models. These models have 
been used to study the mechanisms that lead to mutant Htt protein cleavage or the early stages of HD 
pathogenesis (Gray et al., 2008; Slow et al., 2003).  
 
Viral-mediated gene transfer  
Various viral vectors have been developed and utilized for transferring genes into different 
organs, including the brain (Déglon and Hantraye, 2005; Kay et al., 2001; Kirik and Bjorklund, 2003; 
Lundberg et al., 2008). In fact, the CNS has been used as a target to demonstrate the potential of 
these vectors to transduce cells that have no or very low mitotic activity. The recombinant viral vectors 
utilized for CNS gene transfer studies have been derived from adeno-associated virus (AAV), lentivirus 
(LV), adenovirus (Ad), and herpes-simplex virus (HSV). HSV vectors were the first gene transfer 
approaches investigated for the brain (Federoff et al., 1992; Geller and Breakefield, 1988) and were 
followed by adenoviral vectors (Horellou et al., 1994; Le Gal La Salle et al., 1993). However, the 
efficiency and persistence of transgene expression, as well as the vector safety profiles, all improved 
significantly with the subsequent advent of AAV (Kaplitt et al., 1994; McCown et al., 1996) and 
lentiviral vectors (Blomer et al., 1997; Naldini et al., 1996).  
Recombinant AAV vectors have a cloning capacity of roughly 6 kb, and the only viral elements 
remaining in the recombinant vector are the inverted terminal repeats (ITR) in the distal ends of the 
viral genome, which are structures required for helper virus-mediated replication and capsid 
packaging. Following infection, AAV vectors support transgene expression in post-mitotic cells for the 
lifetime of the individual (Mandel et al., 2006). The only serotype so far utilized in CNS clinical trials 
has been AAV type 2, which has displayed an excellent safety profile (Lim et al., 2010; Mandel et al., 
2006). Recently, other serotypes have become available (Chao et al., 2000). Many of these new AAV 
vectors, such as AAV1 (Passini et al., 2003; Wang et al., 2003), AAV5 (Davidson et al., 2000), AAV8 
(Dodiya et al., 2010), AAV9 (Van der Perren et al., 2011) and AAV10 (Sondhi et al., 2007) display 
greater transduction efficiency, greater diffusion in the brain parenchyma, and higher levels of 
transgene expression than AAV2 (Mandel et al., 2006).  
LV vectors pseudotyped with the VSV-G protein have become some of the most widely used 
vectors for biological research and functional genomics, and this gene transfer technology has now 
reached the clinic (D'Costa et al., 2009; Manilla et al., 2005; Schambach and Baum, 2008). LV 
belongs to a subclass of retroviruses that integrate into the host cell genome, which results in 
persistent expression of the gene of interest. However, in contrast to retroviral vectors, LV vectors 
efficiently transduce non-dividing cells. Moreover, the capacity of LV vectors to accommodate 
relatively large transgenes (up to 9 kb) is an advantage over AAVs. First generation LV vectors, based 
largely on human immunodeficiency virus 1 (HIV-1), included multiple components of the HIV genome. 
Most of these elements have since been removed in the newer generation versions (Zufferey et al., 
1998). Recently, vectors with mutations in the integrase gene were developed to prevent vector 
integration into the host genome and further improve the safety of the system (Banasik and McCray, 
2010). Furthermore, improvements in LV vector technology have facilitated large-scale production of 
recombinant LVs by using stable packaging cell lines (Farson et al., 2001; Klages et al., 2000). VSV-
G-pseudotyped LVs enable transgenes to be locally expressed in neurons because they do not 
undergo anterograde or retrograde transport. This feature is of interest for studying the relationship 
between the regional localization of disease gene expression and resulting behavioral deficits. In 
contrast, AAV vectors lead to more widespread expression. In some cases, anterograde and 
retrograde transport of viral particles can be exploited to replicate pathologies that affect large areas of 
the brain (Hollis et al., 2008; White et al., 2011). Recently, several groups have investigated whether 
viral vectors can be used to develop new animal models of neurodegenerative disorders.  
 
 
Viral vectors to model CNS disorders  
This strategy holds various advantages compared with classical transgenic approaches. Viral 
vector gene transfer can produce local and massive overexpression of a disease gene. This provides 
a rapid, highly flexible and cost-effective, in vivo paradigm to study the impact of pathogenic gene 
expression during CNS development or in adult animals. When the viral vector is injected in adults, it 
avoids the emergence of compensatory mechanisms that may protect the brain from disease-induced 
cell death in transgenic animals. The high transduction efficiencies, as well as ability to deliver robust 
and sustained transgene expression, can lead to the rapid appearance of functional and behavioral 
abnormalities and severe neurodegeneration. Transduced animals can be their own internal control if 
transgene expression is limited to one hemisphere. Multiple genetic models can be created in a short 
period of time. Finally, models can also be established in different mammalian species including non-
human primates (NHP), thereby providing opportunities to assess complex behavioral changes and 
perform longitudinal follow-up of neuropathological alterations by imaging.  
Targeted injections of viral vectors into different brain areas can be used to investigate the 
regional specificity of a neuropathology and eliminate potential side effects associated with 
widespread overexpression of the transgene. In addition, the respective contributions of neuronal and 
non-neuronal cells, which have each been shown to play important roles in neurodegenerative 
diseases, could be addressed with vectors that target specific cell types. By using different AAV 
serotypes, which differ in the receptors utilized for cell entry, or by pseudotyping LVs with rabies or 
mokola viral envelope proteins, the transduction efficiency of certain cell types may be significantly 
altered (Wong et al., 2004). VSV-G-pseudotyped LV and AAV2 have strong neurotropisms (Davidson 
et al., 2000; Naldini et al., 1996). However, LV having an astroglial tropism have been obtained by 
changing the envelope used for the pseudotyping, inserting a tissue-specific promoter and taking 
advantage of microRNA post-transcriptional regulation to suppress residual transgene expression in 
undesired cells ( Colin et al., 2009). This vector offer new opportunities to dissect the contribution of 
glial cells in CNS pathologies such as HD (Faideau et al., 2010). For AAV vectors, astrocyte targeting 
was successfully achieved with AAV1 and AAV5 vectors containing transgenes controlled by glial 
promoters (Davidson et al., 2000; Wang et al., 2003). However, glial cell-specific promoters, such as 
GFAP, do not necessarily preclude transgene expression from being detected in neurons (Jakobsson 
et al., 2004). Conversely, ubiquitous promoters, such as the CMV promoter/enhancer, do not 
necessarily produce high transgene expression levels in all cell types (Cannon et al., 2011; Jakobsson 
et al., 2003). The characterization of new cell-type specific promoters and vectors with various 
tropisms will be essential to further expand tool kit available to model CNS pathologies. For diseases, 
such as Canavan’s disease, in which a role for oligodendrocytes has been implicated, efforts are still 
needed to develop vectors that predominantly target these cells.  
 
Modeling HD by overexpressing expanded polyglutamine tracts in vitro 
LV vectors have been used to express mutant human Htt protein with extended glutamine 
repeats in primary cultures of striatal and cortical neurons. One advantage of this approach is that it 
provides a large amount of material to perform biochemical analyses to explore the mechanisms 
underlying striatal death in HD. Indeed, >90% of the cells are infected with these vectors and express 
the transgene for up to eight weeks (Zala et al., 2005). The in vitro proof-of-principle was performed 
with lentiviral vectors expressing a mutant Htt protein (htt171-82Q) under the control of mouse 
phosphoglycerate kinase 1 (PGK) promoter to generate a chronic model of HD in rat primary striatal 
cultures (Zala et al., 2005). Mutant Htt produced a slowly progressing pathology characterized by the 
appearance of neuritic and nuclear aggregates at one month, followed by neuronal dysfunctions and 
cell death between six and eight weeks. Cortical cultures infected with the same LV-Htt171-82Q vector 
showed no sign of neuronal dysfunction despite accumulation of numerous inclusions, which agrees 
with the selective vulnerability of GABAergic neurons observed in HD patients. This progressive 
striatal pathology contrasts with the rapid appearance of cytoplasmic and nuclear aggregates in 
HEK293 cells 16 hours after being infected with an AAV2 vector expressing a GFP fusion protein gene 
containing 97 CAG repeats (CMV promoter) (Senut et al., 2000). The slow progression of the 
pathology in the lentiviral model, compared with other in vitro models, provides an extended time 
window to dissect the cascade of events leading to striatal cell death and to test experimental 
therapies.  
Owing to the high cloning capacity of adenovirus (E1-deleted, synapsin promoter), several Ad 
vectors expressing mutant or wild-type versions of full-length Htt or N-terminal truncated Htt were 
generated and tested (Huang et al., 2008). In primary striatal cells isolated from E17 mouse embryos, 
the formation of Htt inclusions was considerably delayed in cells expressing mutant full-length Htt 
compared to cells expressing Htt171-128Q. The subcellular locations of these proteins also differed, 
as the mutant full-length Htt protein formed neuritic and cytoplasmic inclusions and the truncated Htt 
fragment was found in nuclear aggregates. 
To determine whether the Htt disease-gene overexpression reproduced the transcriptional 
changes seen in HD, microarray analyses were performed on the LV-Htt171-82Q model (Runne et al., 
2008; Zala et al., 2005). Expression of a wild-type Htt fragment (Htt171-18Q) or a control transgene 
(enhanced GFP) caused only a small number of RNA changes in primary neuronal cultures. The 
transcriptomic effects of mutant Htt were time and polyQ expansion-length dependent, and occurred in 
parallel with other manifestations of polyQ toxicity over 4–8 weeks. Specific changes caused by LV-
mediated Htt171-82Q expression in striatal cells were differential detection of 20% of all mRNA probe 
sets, which accurately recapitulated those observed in human patients. HD-related transcriptomic 
changes were also observed in primary neurons expressing a longer fragment of mutant Htt (Htt853-
82Q) and included gene sets involved in neuronal signaling, neuron differentiation, protein degradation 
and RNA processing. Notably, the transcriptomic concordance coefficient was equivalent to the 
highest-scoring transgenic mouse models of HD (Kuhn et al., 2007) and demonstrated that these 
striatal transcriptome dysregulations could be attributed to the intrinsic effects of mutant Htt (Runne et 
al., 2008). 
Benchoua and collaborators took advantage of this in vitro model to dissect the involvement of 
mitochondrial complex II defects and the role of dopamine in the selective vulnerability of striatal 
neurons (Benchoua et al., 2008; Benchoua et al., 2006). Finally, the LV in vitro HD model has been 
used to assess the potential therapeutic benefit of trophic factors and chaperones (Perrin et al., 2007; 
Zala et al., 2005). 
 
Lentiviral- and AAV-mediated delivery of mutant huntingtin to model HD in vivo 
The first in vivo study in adult rats was performed using an AAV vector for expressing a GFP 
fusion protein containing a long polyQ tract (Senut et al., 2000; Table 1). Intrastriatal injection of this 
vector caused intracytoplasmic and ubiquitinated intranuclear aggregates to form rapidly in neurons. 
This study demonstrated that expression of an Htt polyQ tract throughout life does not necessarily 
induce cell death, but rather that acute overexpression of a polyQ tract in adult neurons is sufficient to 
induce a pathology. In a subsequent study, VSV-G pseudotyped LV vectors encoding the first 171, 
853 or 1520 amino acids of wild-type Htt containing only 19 glutamine repeats or encoding mutant 
forms with polyQ tracts of 44, 66 or 82 residues were produced (de Almeida et al., 2002). The Htt 
mutants induced a pathology characterized by the rapid appearance of either neuritic or nuclear 
ubiquitinated Htt aggregates, or both, followed by neuronal dysfunction and astrogliosis. These 
abnormalities finally led to robust and selective degeneration of medium-sized striatal GABAergic 
neurons after 12 weeks while the large cholinergic interneurons and GABAergic aspiny interneurons 
were spared. In agreement with previous studies of transgenic mice and of presymptomatic patients, 
this model showed that aggregation occurs before ubiquitination (Gomez-Tortosa et al., 2001; Lin et 
al., 2001; Mangiarini et al., 1996). Moreover, a temporal and spatial analysis of the striatum revealed 
that the length of the Htt protein modulates the pathogenesis and that the onset of the pathology 
inversely correlates with the number of CAG repeats. The number of Htt aggregates was significantly 
lower for the longer Htt fragments.  
Régulier and collaborators used tetracycline-regulated lentiviral vectors to generate high 
expression levels of a large Htt fragment corresponding to the first 853 amino acids and induce an 
early pathological onset (Regulier et al., 2003). The expression levels reached with these vectors were 
4- to 5-fold higher than those produced by the vectors containing the constitutive PGK promoter and 
exacerbated the pathology. Overexpression of the TRE-853-82Q protein was associated with a loss of 
the GABAergic marker DARPP-32, the proteolytic release of N-terminal Htt fragments and 
translocation of mutant Htt to the nucleus as early as one month post-injection. Similar results were 
obtained in a transgenic mouse model with inducible expression of full-length mutant Htt (Tanaka et 
al., 2006), which yielded nuclear accumulation of a 60-kDa N-terminal cleavage product. This fragment 
is smaller than calpain- or caspase-derived Htt cleavage products, but it is comparable to a product, 
termed cp-A, which accumulated in the nuclei of cells in a previously described cell model (Lunkes et 
al., 2002).  
The tetracycline operator is not only a strong promoter leading to high transgene expression 
levels but also a system that allows transgene expression to be suppressed by peripheral 
administration of doxycycline (Furth et al., 1994; Kistner et al., 1996). Such conditional expression of 
mutant Htt represents a powerful means of exploring the relationship between mutant protein 
expression and progression of the disease. Blockage of mutant Htt expression revealed that 
continuous expression of the mutant protein is required for maintaining inclusions and for progression 
of the clasping phenotype (Yamamoto et al., 2000). In the LV vector-based model, turning off Htt853-
82Q expression for two months was sufficient to restore DARPP-32 expression and to clear Htt 
aggregates from the striatum of adult rats. Altogether, these data demonstrate the reversibility of Htt-
mediated neuronal damage, which is a key feature favoring the development of effective therapies and 
for determining the time-window of intervention.  
Gene transfer also may be valuable to target a subpopulation of cells and explore its function 
in the pathology. The notion of a non-neuronal component of neurodegenerative disease is becoming 
increasingly regarded as an important aspect of the disease process (Lobsiger and Cleveland, 2007). 
Colin et al. developed a lentiviral vector selectively targeting astrocytes with the G protein envelope of 
the Mokola lyssaviruses which displays a preferential tropism toward astrocytes (Colin et al., 2009) 
combined witha detargeting strategy based a neuronal miRNA to eliminate residual expression in 
neuronal cells. In a subsequent work, this tool was used to evaluate the contribution of astrocytes in 
HD (Faideau et al., 2010). They injected a lentiviral vector expressing the first 171 amino acids of the 
human Htt with normal or expanded glutamine repeat into the striatum of adult mice. At 4 weeks post-
injection, mHtt aggregates were observed in astrocytes and not in neurons, confirming the selectivity 
of the vector. Astrocytes expressing mHtt progressively developed a reactive phenotype and showed 
a marked decreased expression of glutamate transporters and a reduction of glutamate uptake. The 
impairment in glutamate transport and recycling capacity was associated with a significant decrease in 
the expression of two neuronal markers, DARPP32 and NR2B in this model. Moreover, they showed 
that select gene transfer of GLT-1 into striatal astrocytes partially rescues the phenotype. Thus, the 
ability to selectively infect non-neuronal cells may be a key component when developing gene therapy 
based therapeutics for neurodegenerative disease. 
Recently, Franich and collaborators characterized a new model of HD generated using an 
AAV1/2 vector expressing exon 1 of mutant Htt containing 70 CAG repeats (controlled by an NSE 
promoter) (Franich et al., 2008). Quantitative RT-PCR revealed that the level of Htt exon 1 expression 
in the striatum of adult rats was >100-fold higher than the level of endogenous Htt, which explained 
the rapid-onset and severe striatal pathology. By comparison, the expression level produced by the 
LV-Htt171-82Q vector was 25-fold higher than the level of endogenous Htt (Drouet et al., 2009). The 
transduction efficiency and diffusion of the vector throughout the rat striatum appeared to be 
substantially greater with AAV1/2 vectors than with LV vectors and was similar to that reported 
recently using an AAV1/8 vector in mice (DiFiglia et al., 2007). However, striatal neurons were not 
uniformly transduced with this AAV1/2 vector. It transduced high numbers of cholinergic interneurons, 
leading to toxicity and neuronal cell death (2-5 weeks), irrespective of the transgene expressed (wild-
type, mutant Htt or EGFP). Furthermore, robust expression of mutant Htt was detected in the globus 
pallidus and the substantia nigra, produced as a result of axonal transport of AAV particles 
(Chamberlin et al., 1998; Senut et al., 2000). Anterograde transport of AAV has been suggested in 
NHPs, following injection of the caudate or putamen with AAV1, 5 or 8 vectors encoding GFP (Dodiya 
et al., 2010). Cy3-labelled AAV1 and AAV9 capsids are anterogradely transported along axons in 
mice, and transgene expression was detected in synaptically connected areas (Cearley and Wolfe, 
2006; Cearley and Wolfe, 2007). Retrograde transport was observed with AAV1 and AAV5 in the brain 
(Burger et al., 2004). For LV vectors, VSV-G pseudotyped LV vector particles were not transported, 
whereas retrograde transport were observed for LV particles containing a rabies envelope protein 
(Kato et al., 2007; Kato et al., 2011; Mazarakis et al., 2001). These axonal transport properties could 
be exploited to express mutant Htt in distal structures of the basal ganglia, including the cortex, where 
large pyramidal neurons that project to layers V, VI and to a lesser extent, layer III, are preferentially 
lost in HD.  
The large volumes of distribution of newly identified AAV serotypes favor the study of 
behavioral deficits. Motor dysfunctions measured by increases in clasping frequency, footslips during 
beam walking and spontaneous exploratory forepaw movements (cylinder test) have been observed in 
animals injected with AAV1/2- and AAV1/8-based Htt expression vectors (DiFiglia et al., 2007; Franich 
et al., 2008). Moreover, the percentage of clasping days positively correlated with the extent of 
neuronal death observed in the striatum (DiFiglia et al., 2007). In a recent study, Hult and collaborators 
showed that local overexpression of Htt853-79Q or Htt171-79Q (AAV2/5 vector) in the hypothalamus 
was sufficient to recapitulate metabolic disturbances, namely the endocrine abnormalities that 
accompany the obesity observed in BACHD transgenic mice (Hult et al., 2011). To demonstrate that 
obesity was due to hypothalamic dysfunction, AAV5 vectors expressing the Cre recombinase were 
used to selectively inactivate the mutant Htt gene in the hypothalamus. This study illustrated the 
potential of combining gene transfer with transgenic animals to study how mutant Htt disrupts various 
pathways and the complex circuitry involved in the pathogenic process.  
 
Viral vectors to create HD models in large animals  
A large animal HD model would be particularly valuable for the development and validation of 
new therapeutic strategies. NHPs are highly similar to humans in terms of neuroanatomy (organization 
of the basal ganglia), motor behavior (movement repertoire) and cognitive behavioral characteristics 
(Brouillet et al., 1999). In fact, a variety of abnormal movements highly reminiscent of those seen in 
HD patients have been observed in NHPs (Hantraye et al., 1990). Thus, whereas rodent studies are 
highly informative for initial exploratory studies, primate studies are necessary for producing results 
with better therapeutic relevance and higher predictive validity. Another advantage of primate models 
is that non-invasive and high resolution imaging of brain structures through MRI or PET can be used to 
determine the anatomopathological changes associated with HD symptoms and thus can improve our 
understanding of how the degenerative process progresses (Hantraye et al., 1992).  
Initially, specific toxins were employed to generate HD models in primates. While the massive 
cell death produced in the ibotenic-induced exitotoxic lesions (Hantraye et al., 1992) or 3-
nitropropionic acid (3-NP) models (Brouillet et al., 1995) make them good for studying neuroprotective 
therapies for HD, it makes them inefficient for assessing the progressive nature of the disease 
(Roitberg et al., 2002). In addition, there are no clear associations between the mechanisms 
implicated in the generation of HD-like symptoms and the genetic cause of HD. Notably, these models 
lack the Htt cytoplasmic inclusions that are a pathological hallmark of the disease. Although the 
chronic 3-NP model reproduces many phenotypic features of HD, including a frontal-type syndrome 
resembling the cognitive deficit associated with HD, it does not replicate the early events of HD 
pathogenesis that are specifically triggered by mutant Htt (Mittoux et al., 2000; Palfi et al., 1996).  
Thus there is a need for a genetic model of HD in primates in order to develop and validate 
new pre-clinical approaches for HD. Recently, our laboratory scaled-up the LV vector-based modeling 
in NHP in order to recapitulate the behavioral and neuropathological features of HD and to evaluate 
therapeutic strategies in a large animal model (Palfi et al., 2007). LV Htt171-19Q or Htt171-82Q 
vectors were delivered in four tracks located in the pre-commissural, commissural and 
postcommissural sensorimotor region of the dorsolateral putamen. This particular region was targeted 
to replicate the motor abnormalities observed in presymptomatic HD patients and in primates following 
excitotoxic striatal lesions. Similar to what has been observed in rats, lentiviral-mediated delivery of 
Htt171-82Q but not Htt171-19Q led to the formation of neuritic and nuclear ubiquitinated aggregates, 
followed by neuronal dysfunction and astrogliosis (Table 1). Unilateral injections of LV Htt171-82Q 
induce chorea following apomorphine stimulation at nine weeks post-injection. When delivered 
bilaterally, spontaneous chorea occurred at 16 weeks and continued for up to 30 weeks. These data 
demonstrate that the local production of mutant Htt is sufficient to produce spontaneous choreic 
movements in primates. Overexpression of mutant Htt in the dorsolateral putamen reproduced a 
spectrum of basal ganglia motor deficits typical of HD, including hand, leg and head dyskinesia, leg 
dystonia, and even tics. Furthermore, behavioral analysis of these animals showed that their 
neurological deficits progressed in manner similar to the progression seen in HD patients. Initially, an 
early pre-symptomatic stage appears that can be revealed by the administration of the dopamine 
agonist apomorphine, and is followed by a symptomatic phase characterized by spontaneous 
choreiform movements (Klawans et al., 1980). Following our study, Chan and collaborators published 
the first transgenic monkey model of HD (Yang et al., 2008). This remarkable achievement resulted 
from the combined use of lentiviral gene transfer and improvements in transgenic technology. LV 
vectors expressing exon 1 of the human Htt gene with 84 CAG repeats under the control of the 
ubiquitin-C promoter were injected into the perivitelline space of rhesus monkey oocytes. Among the 
five newborns, one survived for a month and exhibited dystonia and chorea two days after birth. 
Unfortunately, most of the monkeys died during the early post-natal period and couldn’t be evaluated 
for behavior (Chan and Yang, 2009; Yang et al., 2008).  
Altogether, these studies with viral-mediated expression of mutant Htt provide a robust in vivo 
genetic model for selective neural degeneration that will facilitate future studies on the pathogenesis of 
cell death and enable pre-clinical screening for HD therapeutics.  
 
From viral vector-based models to potential therapeutic strategies for HD 
These studies support the use of viral vector-mediated gene transfer as a platform for testing 
new therapeutic strategies for this fatal disorder. Currently, HD patients are given general symptomatic 
and non-specific treatments such as antichoreic drugs with tetrabenazine (dopamine antagonist) or 
neuroleptics (Ross and Tabrizi, 2011). However, several clinical trials with drugs for the treatment of 
HD have been initiated recently (Munoz-Sanjuan and Bates, 2011; Walker, 2007). In addition, 
disease-modifying treatments are being investigated that may lead to disease-altering therapies. Also 
being considered are therapeutic strategies aimed at counteracting cellular perturbations and/or those 
that directly target polyQ protein production, cleavage or conformation (Ross and Tabrizi, 2011; 
Zuccato et al., 2010).  
Using either in vitro cellular models or in vivo rodent models of mutant Htt toxicity, we 
demonstrated that brain aging (Diguet et al., 2009), the JNK pathway (Perrin et al., 2009), and the 
phosphorylation state of mutant Htt and histone H3 are playing a role in polyQ toxicity (Colin et al., 
2005; Martin et al., 2011; Pardo et al., 2006). In addition, we have evaluated trophic factors CNTF and 
BDNF (Escartin et al., 2006; Escartin et al., 2007; Zala et al., 2005), the transcriptional regulator 
CA150 (Arango et al., 2006) and chaperones (Perrin et al., 2007) for neuroprotective effects. However, 
the most attractive and promising strategy for the treatment of HD is certainly RNAi. Gene-silencing 
techniques that target polyglutamine-encoding mRNA and block or reduce the production of mutant 
Htt protein, have the potential to halt or, at least, delay the process of neuronal death and therefore 
constitute a promising strategy for HD. Several studies using viral-mediated delivery of short hairpin 
RNAs (shRNAs) have led to reduced Htt transcript levels, decreased formation of inclusions and 
improvements in behavioral tests in HD animal models (Franich et al., 2008; Harper et al., 2005; 
McBride et al., 2008; Rodriguez-Lebron et al., 2005). We have recently demonstrated that coincident 
silencing of the normal endogenous wild-type Htt could be considered as therapeutic strategy (Drouet 
et al., 2009).  
In parallel, we are currently investigating a mutant Htt allele-specific silencing technique, which 
would represent the ultimate solution to blocking polyQ pathogenesis while preserving wild-type Htt 
expression and functions. Single nucleotide polymorphisms (SNPs) have been used to discriminate 
wild-type and mutant transcripts of polyQ-based disorders (Alves et al., 2008; Miller et al., 2003; Xia et 
al., 2004). For HD, SNPs in exons of the Htt gene have been described, and genotypes as well as 
allele frequencies have been reported (Lombardi et al., 2009; Pfister et al., 2009; van Bilsen et al., 
2008). However, appropriate HD animal models are needed to validate this approach in vivo. Indeed, 
knock-in mice do not express human Htt (Menalled, 2005) and transgenic models expressing short N-
terminal fragments of human Htt, such as R6/2 (Mangiarini et al., 1996) and N171-82Q (Schilling et al., 
1999), and viral-based HD models (de Almeida et al. 2002; DiFiglia et al. 2007; Franich et al. 2008) do 
not contain the corresponding SNPs. Finally, transgenic mice expressing full-length Htt possess just 
one human allele (Gray et al., 2008; Slow et al., 2003), which allows efficacy to be analyzed, but not 
selectivity, which is an important aspect of the present strategy. To overcome this issue, we have 
developed new HD models based on LV vector-mediated expression of chimeric mutant Htt reporter 
system that consists of the sequence of the first 171 amino acids of the mutant human Htt fused to the 
Htt exons containing the SNPs (Figure 1; Ruiz et al. unpublished data). These chimeric constructs 
produce a striatal neuropathology similar to the original vector encoding Htt171-82Q (Ruiz et al., 
poster 859.13 at the Society for Neuroscience meeting, San Diego, 2010).  
 
Perspectives 
The efficiency of gene transfer vectors for transduction of the CNS has improved remarkably 
recently, leading to safer vectors and long-term, robust transgene expression in the brain (Lundberg et 
al., 2008; Mandel et al., 2006; Manfredsson and Mandel, 2011; Taymans et al., 2007). These 
improvements, coupled with a progressive understanding of the pathological mechanisms of 
neurodegenerative diseases, have led to the initiation of phase I/II clinical trials with AAV and LV 
vectors for the treatment of PD and AD (Eberling et al., 2008; Kaplitt et al., 2007; Marks et al., 2010; 
Tuszynski et al., 2005).  
In parallel, proof-of-principle studies have demonstrated the usefulness of these vectors not 
only for the delivery of therapeutic candidates but also for the development of HD models in rodents 
and primates (Déglon and Aebischer, 2002; Déglon and Hantraye, 2005; Kirik and Bjorklund, 2003; 
Lundberg et al., 2008). One drawback to these approaches is the necessity to perform these 
experiments in biosafety level 2 laboratories, which are not present in every research center, 
particularly those focused on behavioral studies. Nevertheless, several groups have now successfully 
applied vector-mediated expression to model familial forms of neurodegenerative diseases such as 
Alzheimer’s disease (AD; APP expression), Parkinson’s disease (PD; α-synuclein expression) and 
spinocerebellar ataxia type 3 (SCA3; ataxin-3 expression) (Alves et al., 2008; Kirik et al., 2003; Lawlor 
et al., 2007). In these studies, the local overexpression of mutant genes was associated with severe 
neuropathologies that recapitulated some of the specific features of these disorders (de Almeida et al., 
2002; Kirik et al., 2003; Lawlor et al., 2007; Palfi et al., 2007).  
Infection of a limited number of cells, or a subtype of cells, is particularly suited for dissecting 
the contribution of specific circuitry and pathways in these pathogenic processes. Recently, efforts 
have been devoted to design and characterize cell-specific promoters (Brene et al., 1994 and 2000; 
Mayford et al., 1996; Glover et al., 2002). One can notably mention the pleiade promoter project, a 
consortium initiative aiming at producing a large panels of promoters for selective expression in the 
brain (Portales-Casamar et al., 2010). As alternative to tissue-specific promoters, one can combine 
gene transfer approach, the Cre/loxP system and transgenic mice for deleting endogenous or 
exogenous genes in selective cells or brain areas. Several studies demonstrated that Cre 
recombinase could be effectively delivered to discrete regions of the adult mammalian brain using 
AAV and LV vectors (Ahmed et al., 2004; Pfeifer et al., 2001; Scammell et al., 2003). Using this 
approach, Hult and collaborators showed that hypothalamic inactivation of the mutant Htt gene 
(flanked by loxP sites) with a Cre recombinase-expressing AAV5 vector prevented the development of 
the metabolic phenotype in BACHD mice (Hult et al., 2011). Another strategy to capitalize on the large 
number of Cre transgenic mouse lines is to produce Cre-inducible viral vectors with a double-floxed 
inverted open reading frame (ORF). In these viral vectors, the gene of interest is cloned in the 
antisense orientation and is flanked by two pairs of incompatible lox sites (loxP and lox2722). Upon 
transduction in Cre transgenic lines, Cre-expressing cells invert the transgene ORF in a stable, 
irreversible fashion and thereby activate transgene expression under the control of a strong, 
constitutive promoter present in the viral vector (Gradinaru et al. 2009). 
If these different strategies are interesting to dissect the molecular mechanisms implicated in 
neurodegenerative disorders, a widespread expression of a mutant gene is required to closely 
recapitulate features of neurodegenerative diseases. Several studies have explored methods to 
transduce most brain regions, by optimizing delivery methods or volume and rate of infusion, by 
identifying viral vectors that diffuse efficiently throughout the CNS and by injecting the vectors during 
the neonatal period to exploit the smaller size and immaturity of the brain. The intraventricular injection 
of new AAV serotypes having anterograde and retrograde transport properties into neonatal mice 
resulted in widespread, high-level expression of the transgene (Broekman et al., 2006; Passini et al., 
2003). Recently, Kornum et al., demonstrated that a single injection of AAV5 in the striatum of one-
day-old rat pups transduces more than one million striatal cells, as well as transducing input and 
output areas, large parts of the cortex, substantia nigra, septum, hippocampus, and thalamus (Kornum 
et al., 2010). Combining new AAV serotypes and neonatal injection, not only in rodents but also in 
species closer to humans, should better recapitulate the spectrum of symptoms seen in patients. 
Developing such well-suited animal models of HD will greatly facilitate studies of higher-order 
cognitive function, a devastating feature of the pathology and will be critical for evaluating new 
therapeutic strategies for this fatal disorder.  
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Figure 1. Schematic representation of the viral vector encoding chimeric mutant Htt. We choose SNP within the 
human mutant htt transcript: exon 39 (rs363125). The example of chimeric htt with exon 39 is illustrated: the 
sequence surrounding the SNP (A or C) is fused in frame to the 5’ sequence of mutant htt encoding the first 171 
amino acids. A sequence encoding the HA tag is added at 3’ the end to ensure the detection of all fusion proteins. 
The fusion construct is then cloned in a SIN transfert vector.  
(B) Representation of lentiviral vector expressing the siSNP (example of si39C). The shRNA is cloned 
downstream of a Tet responsive element (TRE) and a H1 promoter in the 3’LTR of the vector. A second 
expression cassette contains a GFP reporter gene under the control of a PGK promoter. The SNP was located at 
the position 10 from the 5’ end of the guide strand of the siRNA. 
 
Table 1. Summary of published reports using lentiviral and AAV vectors to model HD by 
overexpression of mutant Htt. 
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AAV: adeno associated virus; CBA: chicken β-actin promoter; CMV: cytomegalovirus promoter; 
DARPP32: dopamine and cAMP-regulated phosphoprotein of 32 kDa; GP: globus pallidus; Htt: 
huntingtin; Lv: HIV1 derived lentivirus; NeuN: neuronal specific nuclear protein; NSE: neuron-specific 
enolase promoter; PGK: phosphoglycerate kinase 1 promoter; SN: substantia nigra TRE: tetracycline-
regulated; VTA: ventral tegmental area 
